6-bromo-3,4-methylenedioxycinnamic acid | 155814-21-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 6-bromo-3,4-methylenedioxycinnamic acid
• 英文别名: 2-bromo-4,5-methylenedioxycinnamic acid；3t-(6-bromo-benzo[1,3]dioxol-5-yl)-acrylic acid；3-(6-bromo-benzo[1,3]dioxol-5-yl)-acrylic acid；3t-(6-Brom-benzo[1,3]dioxol-5-yl)-acrylsaeure；3-(6-Brom-benzo[1,3]dioxol-5-yl)-acrylsaeure；3-(6-Bromobenzo[d][1,3]dioxol-5-yl)acrylic acid；(E)-3-(6-bromo-1,3-benzodioxol-5-yl)prop-2-enoic acid
• CAS: 155814-21-4
• 化学式: C₁₀H₇BrO₄
• 分子量: 271.067
• InChiKey: FIFYPFARGVBVGX-OWOJBTEDSA-N

物化性质

• 沸点：
  407.3±45.0 °C(Predicted)
• 密度：
  1.778±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-bromo-3,4-methylenedioxycinnamic acid 在 氢溴酸 、 溶剂黄146 作用下， 生成 3-(2-溴-4,5-亚甲二氧基苯基)丙酸
  参考文献：
  名称：

  Haworth; Perkin; Stevens, Journal of the Chemical Society, 1926, p. 1766

  摘要：

  DOI：
• 作为产物：
  描述：

  (6-bromo-benzo[1,3]dioxol-5-ylmethylene)-malonic acid 生成 6-bromo-3,4-methylenedioxycinnamic acid
  参考文献：
  名称：

  Pandya et al., Proceedings - Indian Academy of Sciences, Section A, 1948, # 27, p. 240,242

  摘要：

  DOI：

文献信息

• Oxazolidinone combinatorial libraries, compositions and methods of preparation
  申请人：Gordeev F. Mikhail

  公开号：US20050004174A1

  公开（公告）日：2005-01-06

  Oxazolidinones and methods for their synthesis are provided. Also provided are combinatorial libraries comprising oxazolidinones, and methods to prepare the libraries. Further provided are methods of making biologically active oxazolidinones as well as pharmaceutically acceptable compositions comprising the oxazolidinones. The methods of library preparation include the attachment of oxazolidinones to a solid support. The methods of compound preparation in one embodiment involve the reaction of an iminophosphorane with a carbonyl containing polymeric support.

  本发明提供了氧杂环丙烷酮及其合成方法。还提供了包含氧杂环丙烷酮的组合化学文库以及制备这些文库的方法。此外，还提供了制备生物活性氧杂环丙烷酮的方法以及包含氧杂环丙烷酮的药学可接受组合物的方法。文库制备的方法包括将氧杂环丙烷酮附着到固体支持上。在一种实施例中，化合物制备的方法涉及将亚胺磷酰胺与含有羰基的聚合物支持物反应。
• Discovery of a novel piperlongumine analogue as a microtubule polymerization inhibitor with potent anti-angiogenic and anti-metastatic efficacy
  作者：Jinling Qin、Hongliang Li、Xuan Wang、Yixin Zhang、Yongtao Duan、Yongfang Yao、Hua Yang、Moran Sun

  DOI：10.1016/j.ejmech.2022.114738

  日期：2022.12

  with an IC50 value of 5.8 μM. Further studies elucidated that II-14b showed antitumor activities through multiple mechanisms, including the pruduction of abundant ROS, the dissipation of mitochondrial membrane potential, the accumulation of DNA double-strand breaks, and the induction of cell cycle in G2/M phase. More importantly, we have observed that it possesses potential anti-angiogenesis capabilities

  为了发现同时作用于微管蛋白和血管生成的抗癌药物，我们设计并合成了两个系列的荜茇(PL)衍生物，通过用各种苯并杂环(系列II)取代苯基或将C7-C8烯烃环化成芳香杂环（系列 I）。大多数新化合物对六种癌细胞系表现出比母体药物 PL 更好的抗增殖活性。化合物II-14b在这两个系列中对癌细胞具有最佳的细胞毒性，同时对正常人体细胞的细胞毒性相对较低，对耐药细胞的细胞毒性较高。它破坏细胞微管网络并抑制微管蛋白组装，IC 50值为 5.8 μM。进一步的研究表明， II-14b通过多种机制表现出抗肿瘤活性，包括产生丰富的ROS、耗散线粒体膜电位、积累DNA双链断裂以及诱导细胞周期进入G2/M期。更重要的是，我们观察到它具有潜在的抗血管生成能力，包括在体外和体内抑制HUVEC细胞迁移、侵袭和内皮管形成。体内评估表明II-14b抑制斑马鱼 MGC-803 异种移植肿瘤的生长和转移。这些研究结果表明II-14b是一种高效、无毒的抗肿瘤药物。
• Therapeutic agents for parkinson's disease
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP0590919A1

  公开（公告）日：1994-04-06

  Disclosed as therapeutic agents for Parkinson's disease are xanthine derivatives of the formula (I): in which:    R¹ and R² each represent methyl or ethyl;    R³ represents hydrogen, C₁-C₆ straight or branched chain alkyl or C₂-C₆ straight or branched chain alkenyl or alkynyl;    R⁴ represents C₃-C₈ cycloalkyl; a -(CH₂)n-R⁵ group where n is 0 or an integer of from 1 to 4, and R⁵ represents phenyl, naphthyl or a heterocyclic group or a substituted phenyl, naphthyl or heterocyclic group containing from 1-4 substituents selected from C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy, halogen, nitro, amino, mono- or di-(C₁-C₆) alkylamino, trifluoromethyl, benzyloxy, phenyl, phenoxy or C₁-C₆ alkoxy substituted by hydroxy, C₁-C₆ alkoxy, halogen, amino, azide, carboxy or (C₁-C₆ alkoxy)carbonyl;    or a    group where Y¹ and Y² each represent hydrogen, halogen, or C₁-C₆ straight or branched chain alkyl; and Z represents a    group in which R⁶ represents hydrogen, hydroxy, C₁-C₆ straight or branched chain alkyl, C₁-C₆ straight or branched chain alkoxy, halogen, nitro, or amino, and m represents an integer of from 1 to 4; a phenyl, naphthyl or heterocyclic group or a substituted phenyl, naphthyl or heterocyclic group as defined under R⁵;    and X¹ and X² each represent O or S; or a pharmaceutically acceptable salt thereof.

  作为帕金森病治疗剂公开的是式 (I) 的黄嘌呤衍生物： 其中 R¹ 和 R² 各自代表甲基或乙基； R³ 代表氢、C₁-C₆ 直链或支链烷基或 C₂-C₆ 直链或支链烯基或炔基； R⁴ 代表 C₃-C₈ 环烷基；一个-(CH₂)n-R⁵基团，其中 n 为 0 或 1 至 4 的整数，且 R⁵ 代表苯基、萘基或杂环基，或代表含有 1-4 个选自 C₁-C₆ 烷基的取代基的取代苯基、萘基或杂环基、C₁-C₆烷氧基、羟基、卤素、硝基、氨基、单或双（C₁-C₆）烷基氨基、三氟甲基、苄氧基、苯基、苯氧基或 C₁-C₆烷氧基、苯氧基或被羟基、C₁-C₆ 烷氧基、卤素、氨基、叠氮化物、羧基或 (C₁-C₆ 烷氧基)羰基取代的 C₁-C₆ 烷氧基； 或 其中 Y¹ 和 Y² 分别代表氢、卤素或 C₁-C₆直链或支链烷基的基团；以及 Z 代表一个基团。 其中 R⁶ 代表氢、羟基、C₁-C₆ 直链或支链烷基、C₁-C₆ 直链或支链烷氧基、卤素、硝基或氨基，且 m 代表 1 至 4 的整数的基团；R⁵ 中定义的苯基、萘基或杂环基团或取代的苯基、萘基或杂环基团； 且 X¹ 和 X² 各自代表 O 或 S； 或其药学上可接受的盐。
• Moisture-proof material
  申请人：NITTO DENKO CORPORATION

  公开号：EP2565245A2

  公开（公告）日：2013-03-06

  The present invention relates to a moisture-proof material having a polyurethane film substrate and an adhesive layer formed on at least one surface of the substrate, which material shows a tensile strength of not less than 7500psi, and an elongation at break of not less than 550%.

  本发明涉及一种防潮材料，它具有聚氨酯薄膜基材和形成于基材至少一个表面的粘合剂层，该材料的拉伸强度不小于 7500psi，断裂伸长率不小于 550%。
• Structure-Based Design of a Parallel Synthetic Array Directed Toward the Discovery of Irreversible Inhibitors of Human Rhinovirus 3C Protease
  作者：Theodore O. Johnson、Ye Hua、Hiep T. Luu、Edward L. Brown、Fora Chan、Shao Song Chu、Peter S. Dragovich、Brian W. Eastman、Rose Ann Ferre、Shella A. Fuhrman、Thomas F. Hendrickson、Fausto C. Maldonado、David A. Matthews、James W. Meador、Amy K. Patick、Siegfried H. Reich、Donald J. Skalitzky、Stephen T. Worland、Michelle Yang、Leora S. Zalman

  DOI：10.1021/jm010435c

  日期：2002.5.1

  Utilizing the tools of parallel synthesis and structure-based design, a new class of Michael acceptor-containing, irreversible inhibitors of human rhinovirus 3C protease (HRV 3CP) was discovered. These inhibitors are shown to inhibit HRV-14 3CP with rates of inactivation ranging from 886 to 31400 M-1 sec(-1). These inhibitors exhibit antiviral activity when tested against HRV-14 infected H1-HeLa cells, with EC50 values ranging from 1.94 to 0.15 muM. No cytotoxicity was observed at the limits of the assay concentration. A crystal structure of one of the more potent inhibitors covalently bound to HRV-2 3CP is detailed, These compounds were also tested against HRV serotypes other than type 14 and were found to have highly variable activities.